Cargando…

Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study

Background: Mucinous prostate cancer (PCa) is an extremely rare form of prostate malignancy. To date, the limited knowledge of its biology and outcomes stems from mostly small, single institution experiences. We analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Feng, Yu, Xiaokai, Xu, Mengyou, Ye, Sunyi, Zang, Shoumei, Zhong, Weixiang, Ren, Guoping, Chen, Xin, Yan, Senxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962295/
https://www.ncbi.nlm.nih.gov/pubmed/31998638
http://dx.doi.org/10.3389/fonc.2019.01467
_version_ 1783488133789122560
author Zhao, Feng
Yu, Xiaokai
Xu, Mengyou
Ye, Sunyi
Zang, Shoumei
Zhong, Weixiang
Ren, Guoping
Chen, Xin
Yan, Senxiang
author_facet Zhao, Feng
Yu, Xiaokai
Xu, Mengyou
Ye, Sunyi
Zang, Shoumei
Zhong, Weixiang
Ren, Guoping
Chen, Xin
Yan, Senxiang
author_sort Zhao, Feng
collection PubMed
description Background: Mucinous prostate cancer (PCa) is an extremely rare form of prostate malignancy. To date, the limited knowledge of its biology and outcomes stems from mostly small, single institution experiences. We analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the incidence and treatment of mucinous PCa together with its prognostic factors to gain relatively large and consolidated insights. Methods: Age-adjusted incidence (AAI) rates were evaluated over time. Propensity score matching (PSM) and Kaplan–Meier analyses were used to compare the prognosis between mucinous PCa and typical prostate acinar adenocarcinoma. We assessed cancer-specific survival (CSS) and overall survival (OS) after patient stratification according to summary stage and treatment choice. Cox hazards regression analysis was performed to determine independent predictors of CSS and OS. Results: The AAI in 2016 was 0.24 per million. Patients with mucinous PCa had similar CSS and OS to matched individuals with typical prostate acinar adenocarcinoma. In terms of treatment, 65.3% of mucinous PCa patients underwent surgery, and 23.9% received radiation therapy. Patients who underwent surgery had longer survival (CSS, p = 0.012; OS, p < 0.001), and patients who received radiation therapy had similar survival to those who did not receive radiation therapy (CSS, p = 0.794; OS, p = 0.097). A multivariate Cox analysis for CSS and OS showed that older age (CSS: HR: 4.982, p = 0.001; OS: HR: 4.258, p < 0.001) and distant stage (CSS: HR: 40.224, p < 0.001; OS: HR: 9.866, p < 0.001) were independent prognostic factors for mucinous PCa patients. Conclusions: Mucinous PCa has an extremely low AAI. Analysis of its outcomes indicates that it is not a more malignant tumor as previously suspected. Mucinous PCa shows a similar prognosis to typical prostate acinar carcinoma. Surgery was associated with prolonged survival. An older age at diagnosis and distant stage was associated with poor survival.
format Online
Article
Text
id pubmed-6962295
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-69622952020-01-29 Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study Zhao, Feng Yu, Xiaokai Xu, Mengyou Ye, Sunyi Zang, Shoumei Zhong, Weixiang Ren, Guoping Chen, Xin Yan, Senxiang Front Oncol Oncology Background: Mucinous prostate cancer (PCa) is an extremely rare form of prostate malignancy. To date, the limited knowledge of its biology and outcomes stems from mostly small, single institution experiences. We analyzed the Surveillance, Epidemiology, and End Results (SEER) database to explore the incidence and treatment of mucinous PCa together with its prognostic factors to gain relatively large and consolidated insights. Methods: Age-adjusted incidence (AAI) rates were evaluated over time. Propensity score matching (PSM) and Kaplan–Meier analyses were used to compare the prognosis between mucinous PCa and typical prostate acinar adenocarcinoma. We assessed cancer-specific survival (CSS) and overall survival (OS) after patient stratification according to summary stage and treatment choice. Cox hazards regression analysis was performed to determine independent predictors of CSS and OS. Results: The AAI in 2016 was 0.24 per million. Patients with mucinous PCa had similar CSS and OS to matched individuals with typical prostate acinar adenocarcinoma. In terms of treatment, 65.3% of mucinous PCa patients underwent surgery, and 23.9% received radiation therapy. Patients who underwent surgery had longer survival (CSS, p = 0.012; OS, p < 0.001), and patients who received radiation therapy had similar survival to those who did not receive radiation therapy (CSS, p = 0.794; OS, p = 0.097). A multivariate Cox analysis for CSS and OS showed that older age (CSS: HR: 4.982, p = 0.001; OS: HR: 4.258, p < 0.001) and distant stage (CSS: HR: 40.224, p < 0.001; OS: HR: 9.866, p < 0.001) were independent prognostic factors for mucinous PCa patients. Conclusions: Mucinous PCa has an extremely low AAI. Analysis of its outcomes indicates that it is not a more malignant tumor as previously suspected. Mucinous PCa shows a similar prognosis to typical prostate acinar carcinoma. Surgery was associated with prolonged survival. An older age at diagnosis and distant stage was associated with poor survival. Frontiers Media S.A. 2020-01-09 /pmc/articles/PMC6962295/ /pubmed/31998638 http://dx.doi.org/10.3389/fonc.2019.01467 Text en Copyright © 2020 Zhao, Yu, Xu, Ye, Zang, Zhong, Ren, Chen and Yan. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Zhao, Feng
Yu, Xiaokai
Xu, Mengyou
Ye, Sunyi
Zang, Shoumei
Zhong, Weixiang
Ren, Guoping
Chen, Xin
Yan, Senxiang
Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title_full Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title_fullStr Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title_full_unstemmed Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title_short Mucinous Prostate Cancer Shows Similar Prognosis to Typical Prostate Acinar Carcinoma: A Large Population-Based and Propensity Score-Matched Study
title_sort mucinous prostate cancer shows similar prognosis to typical prostate acinar carcinoma: a large population-based and propensity score-matched study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6962295/
https://www.ncbi.nlm.nih.gov/pubmed/31998638
http://dx.doi.org/10.3389/fonc.2019.01467
work_keys_str_mv AT zhaofeng mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT yuxiaokai mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT xumengyou mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT yesunyi mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT zangshoumei mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT zhongweixiang mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT renguoping mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT chenxin mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy
AT yansenxiang mucinousprostatecancershowssimilarprognosistotypicalprostateacinarcarcinomaalargepopulationbasedandpropensityscorematchedstudy